within Pharmacolibrary.Drugs.ATC.V;

model V10AX04
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 1.6666666666666667e-08,
    adminDuration  = 600,
    adminMass      = 30 / 1000000,   // mg â†’ kg
    adminCount     = 1,
    Vd             = 1e-05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V10AX04</td></tr><td>route:</td><td>intraarticular</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Erbium-169 citrate colloid is a radiopharmaceutical used predominantly for the treatment of chronic synovitis by radiosynovectomy, especially in small joints affected by rheumatoid arthritis. It delivers localized beta radiation after intra-articular injection. Its use is limited to specific therapeutic procedures and it does not have broad regulatory approval for routine use.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic studies available; estimates based on related radiocolloid agents administered intra-articularly for synovectomy.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V10AX04;
